XBiotech (XBIT)

Common Shares

Sell: $2.37|Buy: $3.00|Change: 0.05 (-1.97%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$2.55

Previous close

$2.54

Trade high

$2.55

Volume

55,001

Year high

$8.32

Year low

$2.35

Dividend yield

–

Market capitalisation

$75.91 mn

P/E ratio

1.34

ISIN

CA98400H1029

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 16/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
XBiotech	- 1.97
More...

Company profile

XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.